Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2019-12-06 Regulatory Filings
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 5, 2019. It announces a press release about the initiation of a Phase II clinical trial by American BriVision (Holding) Corporation. The document explicitly states it is a Current Report on Form 8-K and includes a press release as an exhibit. There are no financial statements or detailed financial data included, only a regulatory disclosure of a material event. This type of filing is a regulatory announcement of a material event, not a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS).
2019-12-06 English
QUARTERLY REPORT
Interim / Quarterly Report Q3 2019
2019-11-18 English
NOTIFICATION OF LATE FILING
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the company was unable to file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2019 on time and requests additional time to file it. The document does not contain the actual financial statements or substantive financial data of the 10-Q report but is rather a notification about the delay in filing that report. According to the rules, such a notification is not the report itself but an announcement related to the filing status. Therefore, this document should be classified as a Regulatory Filing (RNS), which is the fallback category for filings that do not fit other specific categories and includes officer certifications, attestations, and notifications of filing delays.
2019-11-13 English
REGISTRATION STATEMENT
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans. It includes detailed information about the stock option plan, the number of shares registered, and the prospectus for resale of shares by selling stockholders. The document is not an annual report, earnings release, or any other financial report but a registration statement related to securities issuance under a stock option plan. This type of filing does not match any of the specific categories related to financial reports or management information but is best classified under Regulatory Filings (RNS) as a general regulatory announcement and compliance document that does not fit other categories.
2019-11-12 English
CURRENT REPORT
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 29, 2019. It reports the entry into a material definitive agreement involving a convertible promissory note and related financing details. The content focuses on a financing transaction, including terms of the note and securities purchase agreement. There are no financial statements or comprehensive financial data presented, nor is it an earnings release or annual/interim report. The document is a regulatory filing reporting a capital raising event and related agreements. According to the filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). Therefore, this document is best classified as CAP.
2019-11-01 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is a 'Current Report' pursuant to the Securities Exchange Act of 1934, dated October 15, 2019. The content describes the issuance of a press release about an investigational report for a feasibility study of a medical device, presented at a conference. There are no financial statements or detailed financial data included, only a disclosure of a press release and forward-looking statements. This type of filing is a regulatory announcement of a material event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2019-10-15 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.